Literature DB >> 24134951

Neuroprotective effect through the cerebral sodium-glucose transporter on the development of ischemic damage in global ischemia.

Shinichi Harada1, Yui Yamazaki, Hiroki Nishioka, Shogo Tokuyama.   

Abstract

Diabetes mellitus and impaired glucose metabolism are the most important risk factors for stroke. We recently demonstrated that cerebral ischemic stress causes hyperglycemia (i.e., post-ischemic hyperglycemia) and may worsen ischemic neuronal damage in a mouse model of focal ischemia. However, the detailed mechanisms are still unknown. The sodium-glucose transporter (SGLT) generates inward currents in the process of transporting glucose into cells, resulting in depolarization and increased excitability, which is well known to be caused by cerebral ischemia. Hence, we focused on the role of SGLT on the development of neuronal damage using a global ischemic model. Male ddY mice were subjected to 30min of bilateral carotid artery occlusion (BCAO). The neuronal damage was estimated by histological analysis using HE staining on day 3 after BCAO. Intraperitoneal (i.p.) administration of phlorizin (a specific and competitive inhibitor of SGLT, 200mg/kg immediately after reperfusion) suppressed the development of post-ischemic hyperglycemia on day 1 after BCAO. In contrast, intracerebroventricular (i.c.v.) administration of phlorizin (40μg/mouse immediately and 6h after reperfusion) had no effect on day 1 after BCAO. Interestingly, the development of ischemic neuronal damage was significantly suppressed by i.p. and i.c.v. administration of phlorizin on day 3 after BCAO. In addition, BCAO-induced spasticity was significantly suppressed by PHZ (40μg/mouse, i.c.v.) from using gait analysis. Our results indicated that cerebral SGLT was involved in the development of ischemic neuronal damage in global ischemia.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Global ischemia; Glucose transporter; Hyperglycemia; Neuroprotection; SGLT

Mesh:

Substances:

Year:  2013        PMID: 24134951     DOI: 10.1016/j.brainres.2013.09.041

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy.

Authors:  Mumin Alper Erdogan; Dimas Yusuf; Joanna Christy; Volkan Solmaz; Arife Erdogan; Emin Taskiran; Oytun Erbas
Journal:  BMC Neurol       Date:  2018-06-07       Impact factor: 2.474

Review 2.  Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review.

Authors:  Thahesh Tharmaraja; Jamie S Y Ho; Ching-Hui Sia; Nicole-Ann Lim; Yao Feng Chong; Amanda Y L Lim; Rahul R Rathakrishnan; Leonard L L Yeo; Vijay K Sharma; Benjamin Y Q Tan
Journal:  Ther Adv Chronic Dis       Date:  2022-04-11       Impact factor: 5.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.